No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
473681 |
1. Apply sex-specific ruleNone |
473681 |
2. Check conditionsNone |
473681 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
306 |
4. Check minimum number of eventsNone |
306 |
5. Include endpointsNone |
306 |
6. Filter based on genotype QC (FinnGen only) |
289 |
Control definitions (FinnGen only)
Control exclude
MYELOPROF
Extra metadata
First used in FinnGen datafreeze
DF2, additional
Similar endpoints
↥List of similar endpoints to
Chronic myeloid leukaemia [CML], BCR/ABL-positive
based on the number of shared cases.
Similar with more cases:
- Myeloid leukaemia
- Myeloid leukaemia
- Myeloproliferative diseases
- Primary_lymphoid and hematopoietic malignant neoplasms
- Primary_lymphoid and hematopoietic malignant neoplasms
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2730 | 1222 | 1459 |
| Only index persons | 1748 | 801 | 947 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 61.57 | 61.90 | 61.03 |
| Only index persons | 59.17 | 59.30 | 59.06 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 289 | 139 | 150 |
| Unadjusted period prevalence (%) | 0.07 | 0.05 | 0.08 |
| Median age at first event (years) | 58.35 | 57.64 | 59.01 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
Mortality – FinRegistry
↥Association
Association between endpoint CML and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CML | 4.426 [3.35, 5.85] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.636 |
During the follow-up period (1.1.1998 — 31.12.2019), 322 out of 808 females with CML died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CML | 3.628 [2.8, 4.71] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 423 out of 944 males with CML died.
Mortality risk
Mortality risk for people of age
years, who have CML.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.525% | 0.565% |
| 5 | 2.993% | 4.051% |
| 10 | 7.101% | 9.458% |
| 15 | 13.164% | 18.283% |
| 20 | 22.051% | 29.576% |
Relationships between endpoints
↥Index endpoint: CML – Chronic myeloid leukaemia [CML], BCR/ABL-positive
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data